



## **Communication – Prescribing of Weight Loss Medications (Tirzepatide / Mounjaro)**

### **Update – Monday 23 June**

You will be aware, from national media announcements that Tirzepatide (Mounjaro) has been declared as available from General Practice from today. The announcements have included mention of strict criteria that must be met, although no official implementation guidance has yet been issued locally by the West Yorkshire ICB. In light of this, and pending formal communication from the ICB, the following update is provided to clarify the current local position for all practices:

#### Criteria – Weight Loss Indication

The following criteria applies to the prescribing of Tirzepatide for weight loss purposes and is the only patient cohort suitable:

- BMI greater than 40
- 4 or more qualifying co-morbidities (hypertension, dyslipidaemia, obstructive sleep apnoea, cardiovascular disease, type 2 diabetes mellitus).
- NICE TA1026 mandates the provision of wraparound care alongside prescribing. This should include nutritional and dietetic advice from a provider meeting the required specifications from NHSe.

#### Please Note the Current Local Position

- At present, there is no Tier 3 Weight Management Service commissioned in Calderdale. A service is under proposal but not yet operational.
- As confirmed today, the West Yorkshire APC still classifies Tirzepatide as a 'Red' for the use of weight management, this means GPs must not initiate or prescribe for this indication. ([Search by individual drug - West Yorkshire ICS Area Prescribing Committee](#)[West Yorkshire ICS Area Prescribing Committee](#))
- NHS England is yet to commission a national wrap-around service as previously planned. We are waiting for confirmation as to their current plans.
- West Yorkshire ICB provided an update on their guidance for the use of Tirzepatide in weight loss on the 22 May, this is available at: [Medicines information :: West Yorkshire Health & Care Partnership](#)
- The BMA have provided updated guidance on the prescribing of Tirzepatide in General Practice. This can be found at: [Focus on: Tirzepatide \(Mounjaro\) for weight management in General Practice](#)
- There is no funding mechanism currently agreed for prescribing Tirzepatide for weight loss in General Practice.

#### Guidance for Practices

- Do not prescribe Tirzepatide (Mounjaro) for weight loss at this time.
- Advise patients that although media announcements have suggested availability, the infrastructure and governance required for safe prescribing are not yet in place.
- Continue to direct patients to existing local weight management services where appropriate.

The LMC is actively engaging with commissioners to clarify future arrangements and will share formal updates as soon as further guidance becomes available.